It's funny, because for one entire year, the main

It's funny, because for one entire year, the main complaint has been no revenue (convertible debt was never accepted for whatever unknown reason). Now there's literally hundreds of thousands of dollars of revenues ($350k announced), I don't see it being reflected in the market.

Patient acquisition always wins for companies generating revenues and profits.

I still stand by my old valuation of where the share price should be based on what's known of the virgin shell. $BCAP is still very undervalued IMO.